PASG - Passage Bio Inc logo

PASG

Passage Bio Inc

Rev โ€”top 1%Net income grew 100% of years5Y
Hold

Passage Bio develops gene therapies targeting central nervous system diseases, focusing on conditions like frontotemporal dementia, Krabbe disease, and metachromatic leukodystrophy. Its key products include PBFT02, PBGM01, and PBKR03.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$19today

Score Overview

1 Year
Scoreโ€”
Net Growth20.67%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth80.52%
Net TrendEvery year
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth67.82%
Net Trend83%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Passage Bio Inc fundamental performance

Across Passage Bio Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 112M to -$ 45M. Revenue increased in 0% of the years measured; net income in 83%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-13
$ 4.58โ€”
1 Year2025-08-13
$ 6.38-28.29%
5 Years2021-08-13
$ 241.60-98.11%
All Time2020-02-28
$ 444.00-98.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 36M$ 24M
2025$ 0.00-$ 45M$ 46M
2024$ 0.00-$ 64M$ 76M
2023$ 0.00-$ 102M$ 114M
2022$ 0.00-$ 136M$ 189M
2021$ 0.00-$ 185M$ 315M
IPO2020$ 0.00-$ 112M$ 304M

Explore beyond PASG

You're looking at Passage Bio Inc. Members apply the same fundamental framework across all 3,859 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies